The Efficacy of Pranoprofen Combined with Recombinant Human Epidermal Growth Factor Eye Drops in the Treatment of Xerophthalmia

WANG Wenqing; YANG Xue; LAN Hong

doi:10.3969/j.issn.1672-7185.2024.01.009

Abstract：Objective To explorer the effect of pranoprofen combined with recombinant human epidermal growth factor(rhEGF)eye drops in the treatment of xerophthalmia.Methods A total of 200 patients with xerophthalmia admitted to Gutian County Hospital from December 2020 to December 2022 were selected.All the patients were divided into a control group and an observation group with 100 cases in each group according to the random number table method.The control group was treated with pranoprofen eye drops,while the observation group was treated with pranoprofen combined with rhEGF eye drops.Both groups were treated continuously for one month.Compare the clinical efficacy of two groups,as well as the tear film rupture time,the length of tear secretion test strips,and the level of inflammatory factors before and after treatment.Results The total clinical effective rate of the observation group was 94.00%,which was significantly higher than the control group's 85.00%(P<0.05).After treatment,the tear film rupture time,tear secretion test strip length,and inflammatory factor levels of the two groups were significantly better than before treatment(P<0.05).After treatment,the observation group had a tear film rupture time of(13.13±2.66)seconds and a tear secretion test strip length of(9.55±2.28)mm/5 min,which were both significantly better than the control group's(9.56±2.95)seconds and(7.88±1.85)mm/5 min(P<0.05).After treatment,the levels of various inflammatory factors in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Pranoprofen combined with rhEGF eye drops can effectively alleviate clinical symptoms,promote tear secretion,and alleviate inflammatory reactions in patients with xerophthalmia,which is worthy of clinical promotion and use.